RSV vaccination for pregnant women - Update SGGG expert letter No. 91

From August 2025, the RSV vaccine Abrysvo® will be included in the specialty list (SL) and will be reimbursed by compulsory health insurance in the following situations: The cost is covered for a single dose for pregnant women between 32 0/7 and 36 0/7 weeks of pregnancy, provided the due date is between October and March. The vaccination can be administered from August 2025. The vaccination is subject to the franchise until December 31, 2025.

The RSV vaccination is used for transplacental immunization of the fetus to protect against RSV infections in newborns and is an alternative to passive immunization of newborns. There is no recommendation preference between the maternal vaccine (Abrysvo®) and the neonatal immunization with the monoclonal antibodies (Nirsevimab, Beyfortus®).

Further information can be found in the updated SGGG expert letter No. 91 (in English - French version will follow shortly).